In this edition, FDA approves first oral therapy for NSCLC, interstitial lung disease diagnosis raises risk for lung cancer and more. Read the full coverage here: FDA approves Hernexeos as first oral therapy for NSCLC with HER2 mutations ILD diagnosis raises risk for lung cancer Uninsured patients benefit less from immune checkpoint inhibitors than privately insured Shared decision-making visit improves annual lung cancer screening adherence Indoor tobacco, e-cigarette use more common in rural vs. urban homes References: Chung Y, et al. CHEST. 2025;doi:10.1016/j.chest.2025.06.026. Press Release Steinberg AW, et al. Ann Am Thorac Soc. 2025;doi:10.1513/AnnalsATS.202504-419OC. Xu H, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.19630. Zhao J, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.19274.

Ver todos los episodios